Yahoo Finance10d
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
We are excited to have Tom at the helm as we develop our RNA/LNP-based genomic medicines." Averna is developing RNA/lipid nanoparticle (LNP)-based genomic medicines to insert genes into "safe ...
The Victoria Advocate10d
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert ...